Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of Typhax, a Typhoid Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adult men or women who are not pregnant or planning to become pregnant during study duration aged 18 to 55 years.~* Clinical laboratory parameters within normal laboratory limits or not found to be clinically significant by the PI~Exclusion Criteria:~* Relevant history of physical or psychiatric illness or medical disorder that required treatment.~* Known or suspected hypersensitivity to investigational product~* Immunocompromised subjects~* Previous Typhoid vaccination or elevated anti-Vi antibodies at screening~* Known history of Typhoid infection in the previous 6 months~* Positive HIV, HBsAg, or HCV screen~* Any other condition or abnormality that, in the opinion of the Investigator, may compromise the safety of the patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Typhax 0.5 mcg (Type: EXPERIMENTAL): Vaccine was administered IM on Days 0 and 28 (n=9).
- Typhax 2.5 mcg (Type: EXPERIMENTAL): Vaccine was administered IM on Days 0 and 28 (n=9).
- Typhax 10 mcg (Type: EXPERIMENTAL): Vaccine was administered IM on Days 0 and 28 (n=9).
- Typhim Vi 25 mcg (Type: ACTIVE_COMPARATOR): Vaccine was administered IM Day 0 (n=9) followed by placebo control on Day 28
- Placebo (saline) (Type: PLACEBO_COMPARATOR): Placebo control was administered IM Days 0 and 28 ( n=9)

Based on this trial design, predict the completion outcome and termination type (if applicable).